Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunotech Biopharm's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$-108.73 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-246.10 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Immunotech Biopharm's annualizedROC % for the quarter that ended in Dec. 2025 was -19.87%.
Immunotech Biopharm's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -47.60%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Immunotech Biopharm's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -43.46%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunotech Biopharm's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunotech Biopharm EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Immunotech Biopharm's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-246.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm (HKSE:06978) has a EBIT of HK$-246.10 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Immunotech Biopharm.
Is Immunotech Biopharm's EBIT too high?
Immunotech Biopharm's current EBIT is HK$-246.10 Mil. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's EBIT compare to VRTX and REGN?
Immunotech Biopharm's EBIT of HK$-246.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Immunotech Biopharm. Immunotech Biopharm's current EBIT is HK$-246.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current EBIT of HK$-246.10 Mil. The current EBIT is HK$-246.10 Mil. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current EBIT is HK$-246.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score
Get the complete analysis for HKSE:06978
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06978 has been successfully added to your 
